Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Theravance Biopharma Inc
TBPHCurrent price
9.23 USD
-0.08 USD (-0.86%)
Last closed
9.28 USD
Company
www.theravance.com
ISIN
KYG8807B1068
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
481 908 160 USD
Yield for 12 month
+6.83 %
1Y
3Y
5Y
10Y
15Y
TBPH
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California. Address: 901 Gateway Boulevard, South San Francisco, CA, United States, 94080
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
13.20 USDP/E ratio
–Dividend Yield
–Current Year
+57 424 000 USD
Last Year
+51 346 000 USD
Current Quarter
+16 868 000 USD
Last Quarter
+14 256 000 USD
Current Year
+16 803 000 USD
Last Year
+44 757 000 USD
Current Quarter
+16 868 000 USD
Last Quarter
+4 302 000 USD
Key Figures TBPH
1 year
3 years
5 years
10 years
EBITDA
-38 236 000 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-6.41 %
PEG Ratio
-0.050
Return On Equity TTM
-22.88 %
Wall Street Target Price
13.20 USD
Revenue TTM
63 192 000 USD
Book Value
3.79 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
7.50 %
Dividend Yield
–
Gross Profit TTM
-12 046 000 USD
Earnings per share
-1.03 USD
Diluted Eps TTM
-1.03 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
-78.18 %
Dividend Analytics TBPH
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History TBPH
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Stock Valuation TBPH
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
11.81
Enterprise Value Revenue
6.89
Price Sales TTM
7.63
Enterprise Value EBITDA
-9.69
Price Book MRQ
2.60
Financials TBPH
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators TBPH
For 52 weeks
7.44 USD
11.71 USD
50 Day MA
9.02 USD
Shares Short Prior Month
4 852 704
200 Day MA
8.87 USD
Short Ratio
19.79
Shares Short
4 317 167
Short Percent
17.05 %
BeatStart